John Greenman

Professor John Greenman

Professor of Tumour Immunology

Faculty and Department

  • Faculty of Health Sciences
  • School of Life Sciences

Summary

John is a tumour immunologist with extensive experience of developing lab on a chip technology for analysing tumour biopsies. He has published over 150 peer-reviewed publications and his immunobiology group works closely with clinicians, chemists and engineers. The majority of his research work has focused on tumours of the head and neck region, identifying novel markers of progression or treatment response. 1991-1995 Post-doctoral Research Fellow, Sir William Dunn School of Pathology, MRC Cellular Immunology Unit, University of Oxford 1995-1999 Lecturer in Immunology, Dept of Surgery, University of Hull 1999-2004 Senior Lecturer in Tumour Immunology, University of Hull 2004- 2009 Reader in Tumour Immunology, University of Hull Currently a member of the NC3Rs David Sainsbury Fellowship Panel 2015 - REF2014 - Appointed as Output Assessor for Panel UoA3 (2014)

Undergraduate

BSc programmes - Clinical Microbiology and Immunology - Professional and Research skills for Biomedical Sciences - Reviews in Biomedical Science - Final Year Research Projects, 20 and 40 credit MSc programmes - Tumour Immunology and Microenvironment - Organ-specific Cancers: From Bench to Bedside - Research Project and Dissertation

Postgraduate

I welcome applications to work with me in either the biomedical applications of microfluidic devices or head and neck immunobiology. These can come from basic scientists or medically trained individuals. Completed PhDs 60 postgraduate (PhD and MD) students successfully supervised since 1999. PhDCheah, R. (2016), Monitoring the Response of Head and Neck Tumour Tissue to Irradiation Using a Microfluidic-Based Approach Smith, J. (2016), The Effect of HNSCC-derived Soluble Factors on the Proliferation and Function of Immune Cells Chandrabalan, K. (2016), A Microfluidic Approach to the Study of Cellular Responses to Oxidative Stress Williamson, J. (2016), The Role of Endothelial Adhesins in Leukocyte Adhesion in Response to Pharmaceutical Agents that Induce Pulmonary Fibrosis Todd, A. (2016), Role of Hypoxia-Induced Adam 10 in Colorectal Cancer Progression Pacelli, A. (2015), Development of a Pet Probe for the Imaging of Cox-2 Expression in Cancers MDPatel, R. (2016), An Observational Pilot Study to Assess the Potential of a Microfluidic Tissue Culture Model to Predict Rectal Cancer Response to Neo-Adjuvant Therapy Zahoor, T. (2016), Does HPV-16 Seropositivity Correlate with T-cell Distribution Providing Additional Prognostic Information in Infected HNSCC Patients? Carr, S. (2013), Assessing the Effects of Radiotherapy on Head and Neck Squamous Cell Carcinoma using Microfluidic Techniques Current PhD supervisors Currently acting as primary and secondary supervisor to 18 postgraduate students covering all aspects of my research interests (three are currently writing up).

Journal Article

Inhibiting arginine methylation as a tool to investigate cross-talk with methylation and acetylation post-translational modifications in a glioblastoma cell line

Samuel, S. F., Marsden, A. J., Deepak, S., Rivero, F., Greenman, J., & Beltran-Alvarez, P. (2018). Inhibiting arginine methylation as a tool to investigate cross-talk with methylation and acetylation post-translational modifications in a glioblastoma cell line. Proteomes, 6(4), doi:10.3390/proteomes6040044

WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer

Poujade, F., Mannion, A., Brittain, N., Theodosi, A., Beeby, E., Leszczynska, K. B., …Pires, I. M. (2018). WSB-1 regulates the metastatic potential of hormone receptor negative breast cancer. The British journal of cancer / Cancer Research Campaign, 118(9), 1229-1237. doi:10.1038/s41416-018-0056-3

Peptidyl-prolyl isomerase 1 (Pin1) preserves the phosphorylation state of tissue factor and prolongs its release within microvesicles

Ettelaie, C., Collier, M., Featherby, S., Greenman, J., & Maraveyas, A. (2017). Peptidyl-prolyl isomerase 1 (Pin1) preserves the phosphorylation state of tissue factor and prolongs its release within microvesicles. BBA - Molecular Cell Research, 1865(1), 12-24. doi:10.1016/j.bbamcr.2017.09.016

Amino acid based gallium-68 chelators capable of radiolabeling at neutral pH

Kubicek, V., Bohmova, Z., Price, T. W., Gallo, J., Kubícek, V., Böhmová, Z., …Stasiuk, G. J. (2017). Amino acid based gallium-68 chelators capable of radiolabeling at neutral pH. Dalton transactions : an international journal of inorganic chemistry / RSoC, 46(48), 16973-16982. doi:10.1039/c7dt03398b

The Role of Chemokines in Thyroid Carcinoma

Yapa, S., Mulla, O., Green, V., England, J., & Greenman, J. (2017). The Role of Chemokines in Thyroid Carcinoma. Thyroid : official journal of the American Thyroid Association, 27(11), 1347-1359. doi:10.1089/thy.2016.0660

Research interests

Coming from an immunology background, Professor Greenman is extremely interested in understanding how the immune system is often subverted during carcinogenesis, and more importantly how such knowledge can be used clinically (diagnostically, prognostically or therapeutically). Current and recent grants H2020-MSCA-RISE-2016, €976,000 (€153k to Hull) (Greenman). Blood test for clinical therapy guidance of non-small cell lung cancer patients. Yorkshire Cancer Research, ?99,198 (Lind and Greenman). Peripheral blood detection of EGFR status in lung cancer patients. 01/11/2016 - 31/10/2018 Innovate UK/EPSRC ?496,000 (?193k to Hull) (Greenman, Green, Cawthorne). Development of a multi-purpose small animal phantom for pre-clinical radiotherapy studies. 01/03/2016 - 28/02/2018. Yorkshire Cancer Research ?123,312 (Archibald, Madden & Greenman). Chemokine receptor targeted therapies. 01/02/2014 - 31/01/2016. British Lung Foundation ?24,800 (Loveday, Lind, Haswell & Greenman). Development of microfluidic device for response to chemotherapy in malignant mesothelioma. 01/10/2013 - 30/09/2015. Technology Strategy Board Sepsis I: Multi-pathogen detection and/or simple discrimination ?399,000 (Greenman, Dyer, Haswell, BioGene Ltd). Rapid, on-chip, multiplexed detection of sepsis-causing organisms from blood samples. 01/09/2012 - 31/08/2015. FP7-SME-2012. Point-of-care blood device for fast and reliable prediction of drug response in non-small cell lung carcinoma patients from blood samples (LungCARD 315586) University of Hull (Haswell & Greenman); Hull and East Riding NHS Trust (Lind & Greenman) (?306,000 to Hull; 1.2M Euro total) 01/01/2013 - 28/2/2014. NC3R ?450,000 (Greenman, Madden, Flynn, Haswell, Maraveyas). Replacement of animal models for tumour biology with a multifunctional microfluidic-based approach. 01/10/2011 - 30/09/2014. NIHR (i4i programme). ?667,542 (Elliott, Wadhawan, Singh, MacFie, Greenman). Development of a placement sensing nasogastric tube. 01/07/2011 - 30/06/2014. Hull and East Riding Cardiac Trust. ?76,128 (Greenman, Jones, Dyer, Wadhawan, Haswell, Griffin, Seymour) Integrated microfluidic devices for real-time measurement of biochemical changes in heart tissue. 01/03/2011 - 30/11/2012. Heart Research UK ?199,728 (Greenman, Haswell and Seymour). Development of microfluidic devices for analysis of function in normal and diseased cardiac tissue. 10/2007 - 09/2011. EPSRC EP/H007385 ?210,949 (Haswell & Greenman). Commercialisation of lab-on-a-chip technology for DNA profiling. 08/2009 - 07/2010.

Project

Funder

Grant

Started

Status

Project

Lungcard 2: Peripheral Blood detection of EGFR status in lung cancer patients

Funder

YCR Yorkshire Cancer Research

Grant

Started

1 November 2016

Status

Complete